Memantine and Whole-Brain Radiotherapy in Brain Metastases

NRG-CC001, A Randomized, Phase III Trial Of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases

November 22, 2017

  • Clinical Trial Information

    Trial Contact: Ford, Elizabeth

    Trial Phone: 321.841.7413

  • IRB No: NRG-CC001

    Protocol Abbrev: NRG-CC001

    Principal Investigator: Naren Ramakrishna, MD, PhD

    Sub Investigators: Avgeropoulos, Nicholas MD

    Phase: Drug: Phase III

    Age Group: Adult

    Secondary Protocol No: NRG-CC001

    Treatment: Medication

    Applicable Disease Sites: Brain Cancer

    Therapies Involved: Memantine and Whole-brain Radiotherapy ID: NCT02360215

  • Objective

    This randomized phase III trial compares memantine hydrochloride and whole-brain radiotherapy with or without hippocampal avoidance in reducing neurocognitive decline in patients with cancer that has spread from the primary site (place where it started) to the brain. Whole brain radiotherapy (WBRT) is the most common treatment for brain metastasis. Unfortunately, the majority of patients with brain metastases experience cognitive (such as learning and memory) deterioration after WBRT. Memantine hydrochloride may enhance cognitive function by binding to and inhibiting channels of receptors located in the central nervous system. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Using radiation techniques, such as intensity modulated radiotherapy to avoid the hippocampal region during WBRT, may reduce the radiation dose to the hippocampus and help limit the radiation-induced cognitive decline. It is not yet known whether giving memantine hydrochloride and WBRT with or without hippocampal avoidance works better in reducing neurocognitive decline in patients with brain metastases.

  • Key Eligibility

    18 Years and older
    Metastatic Malignant Neoplasm in the Brain